Onkure Therapeutics Inc (OKUR) USD0.0001
0.87%- This stock can be held in a
Stocks and Shares ISA
$0.05
(1.16%)$0.05
(1.16%)Company Information
About this company
OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The Company is developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3KαH1047R mutations, including breast cancer. The Company is also focused on targeting oncogenic PI3Kα and has multiple programs designed to enable targeting of this key oncogene.
Key people
Key facts
- EPICOKUR
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS68277Q1058
- Market cap$59.92m
- Employees46
- Shares in issue12.75m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.